(Q37581211)

21 August 2017

title

The cost-benefit approach to pricing new medicines: doxazosin versus beta-blocker treatment in Sweden (English)

1 reference

21 August 2017

0 references

Lindgren B

1

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 March 1990

1 reference

21 August 2017

published in

American Heart Journal

1 reference

21 August 2017

volume

119

1 reference

21 August 2017

issue

3 Pt 2

1 reference

21 August 2017

page(s)

748-753

1 reference

A long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate essential hypertension

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980056-0

Plasma lipid lowering effects of doxazosin, a new selective alpha1 adrenergic inhibitor for systemic hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980056-0

Serum lipid changes in a one-year, multicenter, double-blind comparison of doxazosin and atenolol for mild to moderate essential hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980056-0

Multicenter, double-blind comparison of doxazosin and atenolol in patients with mild to moderate hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980056-0

A double-blind parallel trial to assess the efficacy of doxazosin, atenolol and placebo in patients with mild to moderate systemic hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980056-0

10.1016/S0002-8703(05)80056-0

7 January 2021

Identifiers

DOI

1 reference

21 August 2017

1 reference